Ask AI
ProCE Banner Activity

CE

SC ICI Delivery Strategies: Supporting Clinical Data for SC Immunotherapies 

Text Module

Recent clinical trial data and patient-reported outcomes have raised important questions about how subcutaneous immune checkpoint inhibitor (ICI) formulations compare with intravenous administration in oncology practice. In this activity, learners will examine pharmacokinetic, efficacy, safety, and patient preference findings from studies of SC nivolumab and pembrolizumab, as well as emerging trial data across solid tumors and how these data inform patient counseling, route-of-administration discussions, treatment convenience, safety monitoring, and pharmacy-led implementation of SC ICI therapy.

Pharmacists: 0.50 contact hour (0.05 CEUs)

Released: July 13, 2026

Expiration: January 12, 2027

Share

Provided by

Provided by ProCE, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Merck Sharp & Dohme LLC.

Merck Sharp & Dohme LLC

Target Audience

This activity has been designed to meet the educational needs of pharmacists and other healthcare professionals caring for patients with solid tumors.  

Program Learning Goal

The activity aims to improve learners’ knowledge, confidence, and competence in educating and caring for patients with solid tumors receiving subcutaneous immune checkpoint inhibitors.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Analyze the pharmacy practice implications of current and emerging data on subcutaneous ICIs for cancer treatment

  • Integrate comprehensive knowledge of SC ICI therapies into pharmacy practice, focusing on preparation and administration technique, safety monitoring and management of drug-related complications, and coordination of complex regimens to optimize patient-centered care

Financial Disclosures

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Shawna Kraft, PharmD, BCOP, has no relevant financial relationships to disclose.

Kelly Romo, PharmD, BCOP: consultant/advisor/speaker: Lilly, Pfizer, Sanofi.

The planners and content peer reviewers from ProCE, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from July 13, 2026, through January 12, 2027:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Additional Disclosures

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-26-015-H01-P has been assigned to this home study application-based activity. This activity is approved for 0.5 contact hours (0.05 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 65% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.deceraclinical.com/education, and proof of completion will be posted in NABP CPE Monitor profiles.